Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Accumulated Expenses (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Accumulated Expenses for 4 consecutive years, with $6.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses rose 159.96% to $6.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.8 million, a 159.96% increase, with the full-year FY2024 number at $2.6 million, down 1.84% from a year prior.
  • Accumulated Expenses was $6.8 million for Q3 2025 at Orchestra BioMed Holdings, up from $2.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $6.8 million in Q3 2025 to a low of $202931.0 in Q1 2022.
  • A 4-year average of $2.4 million and a median of $2.5 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 347.94% in 2023, then fell 1.84% in 2024.
  • Orchestra BioMed Holdings' Accumulated Expenses stood at $2.5 million in 2022, then grew by 7.3% to $2.7 million in 2023, then dropped by 1.84% to $2.6 million in 2024, then surged by 161.75% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Accumulated Expenses are $6.8 million (Q3 2025), $2.0 million (Q2 2025), and $2.6 million (Q4 2024).